Medical - Healthcare Information Services
Compare Stocks
2 / 10Stock Comparison
BEAT vs HSDT
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Devices
BEAT vs HSDT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Medical - Healthcare Information Services | Medical - Devices |
| Market Cap | $36M | $89M |
| Revenue (TTM) | $0.00 | $6M |
| Net Income (TTM) | $-21M | $-41M |
| Gross Margin | — | 91.7% |
| Operating Margin | — | -351.0% |
| Total Debt | $0.00 | $0.00 |
| Cash & Equiv. | $4M | $7M |
BEAT vs HSDT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Nov 21 | May 26 | Return |
|---|---|---|---|
| HeartBeam, Inc. (BEAT) | 100 | 24.9 | -75.1% |
| Solana Company (HSDT) | 100 | 0.0 | -100.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: BEAT vs HSDT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
BEAT has the current edge in this matchup, primarily because of its strength in income & stability and long-term compounding.
- beta 1.27
- -81.0% 10Y total return vs HSDT's -100.0%
- Lower volatility, beta 1.27
HSDT is the clearest fit if your priority is growth exposure.
- Rev growth 10.6%, EPS growth 57.3%, 3Y rev CAGR 97.0%
- 10.6% revenue growth vs BEAT's -100.0%
- -20.7% ROA vs BEAT's -353.1%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 10.6% revenue growth vs BEAT's -100.0% | |
| Stability / Safety | Beta 1.27 vs HSDT's 2.65 | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | -50.8% vs HSDT's -99.0% | |
| Efficiency (ROA) | -20.7% ROA vs BEAT's -353.1% |
BEAT vs HSDT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
BEAT vs HSDT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
HSDT leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
HSDT and BEAT operate at a comparable scale, with $6M and $0 in trailing revenue.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $0 | $6M |
| EBITDAEarnings before interest/tax | -$21M | -$21M |
| Net IncomeAfter-tax profit | -$21M | -$41M |
| Free Cash FlowCash after capex | -$15M | -$17M |
| Gross MarginGross profit ÷ Revenue | — | +91.7% |
| Operating MarginEBIT ÷ Revenue | — | -3.5% |
| Net MarginNet income ÷ Revenue | — | -6.8% |
| FCF MarginFCF ÷ Revenue | — | -2.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +33.4% |
| EPS Growth (YoY)Latest quarter vs prior year | +22.2% | +3.9% |
Valuation Metrics
Evenly matched — BEAT and HSDT each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $36M | $89M |
| Enterprise ValueMkt cap + debt − cash | $31M | $82M |
| Trailing P/EPrice ÷ TTM EPS | -1.44x | -1.20x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 14.87x |
| Price / BookPrice ÷ Book value/share | 11.53x | 0.16x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
HSDT leads this category, winning 5 of 5 comparable metrics.
Profitability & Efficiency
HSDT delivers a -105.0% return on equity — every $100 of shareholder capital generates $-105 in annual profit, vs $-6 for BEAT. On the Piotroski fundamental quality scale (0–9), HSDT scores 4/9 vs BEAT's 1/9, reflecting mixed financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | -5.7% | -105.0% |
| ROA (TTM)Return on assets | -3.5% | -20.7% |
| ROICReturn on invested capital | — | -10.8% |
| ROCEReturn on capital employed | -4.6% | -14.0% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 4 |
| Debt / EquityFinancial leverage | — | — |
| Net DebtTotal debt minus cash | -$4M | -$7M |
| Cash & Equiv.Liquid assets | $4M | $7M |
| Total DebtShort + long-term debt | $0 | $0 |
| Interest CoverageEBIT ÷ Interest expense | — | -63.39x |
Total Returns (Dividends Reinvested)
BEAT leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in BEAT five years ago would be worth $1,898 today (with dividends reinvested), compared to $0 for HSDT. Over the past 12 months, BEAT leads with a -50.8% total return vs HSDT's -99.0%. The 3-year compound annual growth rate (CAGR) favors BEAT at -25.2% vs HSDT's -92.8% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | -63.4% | -28.2% |
| 1-Year ReturnPast 12 months | -50.8% | -99.0% |
| 3-Year ReturnCumulative with dividends | -58.2% | -100.0% |
| 5-Year ReturnCumulative with dividends | -81.0% | -100.0% |
| 10-Year ReturnCumulative with dividends | -81.0% | -100.0% |
| CAGR (3Y)Annualised 3-year return | -25.2% | -92.8% |
Risk & Volatility
BEAT leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
BEAT is the less volatile stock with a 1.27 beta — it tends to amplify market swings less than HSDT's 2.65 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. BEAT currently trades 22.3% from its 52-week high vs HSDT's 0.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.27x | 2.65x |
| 52-Week HighHighest price in past year | $4.00 | $258.50 |
| 52-Week LowLowest price in past year | $0.54 | $1.61 |
| % of 52W HighCurrent price vs 52-week peak | +22.3% | +0.9% |
| RSI (14)Momentum oscillator 0–100 | 39.0 | 54.2 |
| Avg Volume (50D)Average daily shares traded | 1.6M | 295K |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
HSDT leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). BEAT leads in 2 (Total Returns, Risk & Volatility). 1 tied.
BEAT vs HSDT: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Which is the better long-term investment — BEAT or HSDT?
Over the past 5 years, HeartBeam, Inc.
(BEAT) delivered a total return of -81. 0%, compared to -100. 0% for Solana Company (HSDT). Over 10 years, the gap is even starker: BEAT returned -81. 0% versus HSDT's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
02Which is safer — BEAT or HSDT?
By beta (market sensitivity over 5 years), HeartBeam, Inc.
(BEAT) is the lower-risk stock at 1. 27β versus Solana Company's 2. 65β — meaning HSDT is approximately 108% more volatile than BEAT relative to the S&P 500.
03Which is growing faster — BEAT or HSDT?
On earnings-per-share growth, the picture is similar: Solana Company grew EPS 57.
3% year-over-year, compared to 15. 1% for HeartBeam, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
04Which has better profit margins — BEAT or HSDT?
HeartBeam, Inc.
(BEAT) is the more profitable company, earning 0. 0% net margin versus -679. 6% for Solana Company — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BEAT leads at 0. 0% versus -351. 0% for HSDT. At the gross margin level — before operating expenses — HSDT leads at 91. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — BEAT or HSDT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is BEAT or HSDT better for a retirement portfolio?
For long-horizon retirement investors, HeartBeam, Inc.
(BEAT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 27)). Solana Company (HSDT) carries a higher beta of 2. 65 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (BEAT: -81. 0%, HSDT: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between BEAT and HSDT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: BEAT is a small-cap quality compounder stock; HSDT is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.